Hormonal
Obesity increases the risk of postmenopausal estrogen receptor-positive (ER+) breast cancer and is associated with worse disease outcomes and higher mortality across all breast cancer subtypes.
For postmenopausal women, maintaining a healthy weight is critical to reducing the risk of developing estrogen-receptor-positive breast cancer and improving survival rates if diagnosed. This is achieved through lifestyle interventions that lower circulating estrogens and inflammatory markers.
Obesity consistently associates with higher postmenopausal breast cancer risk in many studies... Obesity is associated both with a higher risk of developing breast cancer, particularly in postmenopausal women, and with worse disease outcome for women of all ages.
Why this rating
Supported by large prospective cohort studies (Million Women Study), multiple meta-analyses, and consistent observational data.
Source
Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention
Manuel Picon‐Ruiz et al. · CA A Cancer Journal for Clinicians · 2017
DOI 10.3322/caac.21405
More from this paper
- Obesity promotes aggressive breast cancer behavior (growth, invasion, metastasis) through a mechanism involving hypoxia-induced inflammation, increased aromatase expression, and stimulation of cancer stem cells.Good
- Obesity is associated with an increased risk of triple-negative breast cancer (TNBC) in premenopausal women, whereas this association is null or inverse in postmenopausal women.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →